382 related articles for article (PubMed ID: 36344072)
1. The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation.
Caverly LJ; Riquelme SA; Hisert KB
Clin Chest Med; 2022 Dec; 43(4):647-665. PubMed ID: 36344072
[TBL] [Abstract][Full Text] [Related]
2. Highly effective cystic fibrosis transmembrane conductance (regulator) modulator therapy: shifting the curve for most while leaving some further behind.
Chun SW; Somers ME; Burgener EB
Curr Opin Pediatr; 2024 Jun; 36(3):290-295. PubMed ID: 38411576
[TBL] [Abstract][Full Text] [Related]
3. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
[TBL] [Abstract][Full Text] [Related]
4. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
5. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy.
Lahiri T; Sullivan JS
Pediatr Pulmonol; 2022 Feb; 57 Suppl 1():S60-S74. PubMed ID: 34473419
[TBL] [Abstract][Full Text] [Related]
7. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
8. Ocular development after highly effective modulator treatment early in life.
Zhu Y; Li D; Reyes-Ortega F; Chinnery HR; Schneider-Futschik EK
Front Pharmacol; 2023; 14():1265138. PubMed ID: 37795027
[TBL] [Abstract][Full Text] [Related]
9. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
10. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
McPhail GL; Clancy JP
Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Highly Effective Cystic Fibrosis Transmembrane Conductance Regulator Modulators on the Health of Female Subjects With Cystic Fibrosis.
Taylor-Cousar JL; Shteinberg M; Cohen-Cymberknoh M; Jain R
Clin Ther; 2023 Mar; 45(3):278-289. PubMed ID: 36841738
[TBL] [Abstract][Full Text] [Related]
12. Cystic fibrosis transmembrane conductance receptor modulator therapy in cystic fibrosis, an update.
Egan ME
Curr Opin Pediatr; 2020 Jun; 32(3):384-388. PubMed ID: 32374578
[TBL] [Abstract][Full Text] [Related]
13. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.
Hisert KB; Heltshe SL; Pope C; Jorth P; Wu X; Edwards RM; Radey M; Accurso FJ; Wolter DJ; Cooke G; Adam RJ; Carter S; Grogan B; Launspach JL; Donnelly SC; Gallagher CG; Bruce JE; Stoltz DA; Welsh MJ; Hoffman LR; McKone EF; Singh PK
Am J Respir Crit Care Med; 2017 Jun; 195(12):1617-1628. PubMed ID: 28222269
[TBL] [Abstract][Full Text] [Related]
14. Update on Clinical Outcomes of Highly Effective Modulator Therapy.
Gifford AH; Taylor-Cousar JL; Davies JC; McNally P
Clin Chest Med; 2022 Dec; 43(4):677-695. PubMed ID: 36344074
[TBL] [Abstract][Full Text] [Related]
15. Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.
Mall MA; Mayer-Hamblett N; Rowe SM
Am J Respir Crit Care Med; 2020 May; 201(10):1193-1208. PubMed ID: 31860331
[TBL] [Abstract][Full Text] [Related]
16. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
Harris JK; Wagner BD; Zemanick ET; Robertson CE; Stevens MJ; Heltshe SL; Rowe SM; Sagel SD
Ann Am Thorac Soc; 2020 Feb; 17(2):212-220. PubMed ID: 31604026
[No Abstract] [Full Text] [Related]
17. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
Rowe SM; Heltshe SL; Gonska T; Donaldson SH; Borowitz D; Gelfond D; Sagel SD; Khan U; Mayer-Hamblett N; Van Dalfsen JM; Joseloff E; Ramsey BW;
Am J Respir Crit Care Med; 2014 Jul; 190(2):175-84. PubMed ID: 24927234
[TBL] [Abstract][Full Text] [Related]
18. Delivering a New Future for People With Cystic Fibrosis.
Burgener EB; Cornfield DN
Pediatrics; 2023 Oct; 152(4):. PubMed ID: 37671451
[TBL] [Abstract][Full Text] [Related]
19. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
20. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
